Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1219-1223

  Koo, Yu Xuan ^a,b   Tay, Matthew ^a,b   Teh, Yii Ean ^a,b   Teng, David ^a,b   Tan, Daniel S W ^a   Tan, Iain B H ^a   Tai, David W M ^a   Quek, Richard ^a   Tao, Miriam ^a   Lim, Soon Thye ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antibodies; Hepatitis B surface antigens; Hepatitis B virus; Lamivudine; Lymphoma; Monoclonal; Non Hodgkin; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; VIRUS REACTIVATION; B CELL LYMPHOMA; BLOOD; COHORT ANALYSIS; DRUG EFFECT; IMMUNOLOGY; MIDDLE AGED; NONHODGKIN LYMPHOMA; PHYSIOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SINGAPORE; VIRUS ACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SINGAPORE; VIRUS ACTIVATION;

EID: 80055100653     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1241-0     Document Type: Article

References (17)

1. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST (2010) Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116(1):115-121. doi:10-1002/cncr.24742
2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (18):4117-4126. doi:10-1200/JCO.2005-09.131 (Pubitemid 46211317)
3. Dall'Era M, Wofsy D (2010) Biologic therapy for systemic lupus erythematosus. Discov Med 9(44):20-23
4. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9):767-776. doi:10-1177/0961203309106174
5. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK (2006) Kinetics and risk of de novo hepatitis B infection in HBsAgnegative patients undergoing cytotoxic chemotherapy. Gastroenterology 131(1):59-68. doi:10-1053/j.gastro.2006-04.015 (Pubitemid 44015749)
6. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E (2009) Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20(12):2013-2017
7. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27(4):605-611. doi:10-1200/JCO.2008-18.0182
8. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. doi:10-1200/JCO.2010-29.7531
9. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 85(3):243-250. doi:10-1111/j.1600- 0609-2010.01474.x
10. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20- positive B-cell lymphoma. Cancer. doi:10-1002/cncr.25253
11. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89(3):255-262. doi:10-1007/s00277-009-0806-7
12. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519-528 (Pubitemid 351665421)
13. Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136(5):699-712. doi:10-1111/j.1365-2141-2006.06465.x
14. Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113 (14):3147-3153. doi:10-1182/blood-2008-10-163493
15. Delaney WE 4th, Borroto-Esoda K (2008) Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 8 (5):532-540
16. Firpi RJ, Nelson DR (2008) Management of viral hepatitis in hematologic malignancies. Blood Rev 22(3):117-126
17. Cheng PN, Chang TT (2008) Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 6(5):569-579